title: Implementation of guidelines for preventing early onset group B streptococcal infection.
abstract: Early onset Group B Streptococcus (EOGBS) disease, defined by an onset within the first 72 hours of life, occurs in 1.3 to 3.7 per 1,000 live births. The authors sought to determine the impact of the new CDC/AAP/ACOG guidelines on the prepartum screening practice, intrapartum management, incidence of EOGBS infection, and evaluation of neonates born to GBS colonized women at University Macdonald Women's Hospital (Cleveland, OH). A retrospective analysis by chart review was conducted from January 1, 1995 to December 31, 1997 of women identified as GBS colonized during prenatal screening. These women were then divided into 2 groups: period I, women who delivered January 1, 1995 to June 30, 1996 (before institutional implementation of the guidelines for management of GBS colonization]; and period II, women who delivered July 1, 1996 to December 31, 1997 after implementation of the guidelines. A chart review was conducted for infants 72 hours old, and GBS culture positive (blood or CSF) for the same time period. In complying with the new screening and treatment guidelines, there was a significant increase in the number of mothers screened and the detection of maternal colonization, plus a 63% reduction in EOGBS. There was also a substantial reduction in the number of invasive procedures on the neonates. The authors conclude that the new guidelines are both medically and economically effective.
authors.affiliation: Department of Pediatrics, University Hospitals of Cleveland, OH, USA.
authors.forename: L
authors.initials: L
authors.lastname: Share
authors.forename: S
authors.initials: S
authors.lastname: Chaikin
authors.forename: S
authors.initials: S
authors.lastname: Pomeranets
authors.forename: R
authors.initials: R
authors.lastname: Kiwi
authors.forename: M
authors.initials: M
authors.lastname: Jacobs
authors.forename: A A
authors.initials: AA
authors.lastname: Fanaroff
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016470:Bacteremia; D002487:Centers for Disease Control and Prevention, U.S.; D002821:Chorioamnionitis / Q000382:microbiology; D005260:Female; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D017410:Practice Guidelines as Topic; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000382:microbiology; D011296:Prenatal Diagnosis; D012007:Rectum / Q000382:microbiology; D012189:Retrospective Studies; D013290:Streptococcal Infections / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control*; D013292:Streptococcus agalactiae / Q000302:isolation & purification; D014481:United States; D014552:Urinary Tract Infections / Q000382:microbiology; D014621:Vagina / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents